

FORM 62-103F3

**REPORT UNDER PART 4 OF
NATIONAL INSTRUMENT 62-103**

Item 1 – Security and Reporting Issuer

- 1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.

This report relates to the common shares ("**Common Shares**") in the capital of:

Medexus Pharmaceuticals Inc. (the "**Issuer**")
10 King Street East
Suite 600
Toronto, Ontario
M5C 1C3

- 1.2 State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.

Not applicable.

Item 2 – Identity of the Eligible Institutional Investor

- 2.1 State the name and address of the eligible institutional investor.

Armistice Capital LLC ("**Armistice**")
510 Madison Avenue
7th Floor
New York, NY 10022
U.S.A.

- 2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.

On October 6, 2023, the Issuer completed a bought deal public offering of units 3,389,900 ("**Units**") at a price of C\$2.95 per Unit for aggregate gross proceeds of \$10,000,205 (the "**Offering**"). Each Unit consists of one Common Share and one-half of one common share purchase warrant ("**Warrant**") of the Issuer. Each warrant entitles the holder to purchase one Common Share at an exercise price of \$3.65 at any time up to April 6, 2026.

On October 16, 2023, the Issuer fully repaid 6% unsecured convertible debentures due October 16, 2023 ("**Debentures**") in cash.

On October 17, 2023, the over-allotment option provided in connection with the Offering (the “**Over-Allotment Option**”) was exercised resulting in the issuance of an additional 508,484 Units.

Prior to October 16, 2023, Armistice, on behalf of certain investment funds managed by it, was a holder of Debentures. The requirement to file this report was triggered when Armistice, on behalf of certain investment funds managed by it, participated in each of the Offering and the Over-Allotment Option and acquired an aggregate of 3,308,484 Units.

2.3 State the name of any joint actors.

Not applicable.

2.4 State that the eligible institutional investor is eligible to file reports under Part 4 in respect of the reporting issuer.

Armistice is eligible to file reports under Part 4 of National Instrument 62-103 (“**NI 62-103**”) in respect of securities of the Issuer.

Item 3 – Interest in Securities of the Reporting Issuer

3.1 State the designation and the net increase or decrease in the number or principal amount of securities, and in the eligible institutional investor’s securityholding percentage in the class of securities, since the last report filed by the eligible institutional investor under Part 4 or the early warning requirements.

Since the last report dated November 9, 2018, Armistice, on behalf of certain investment funds managed by it, has: (i) been repaid the amounts owing in respect of the Debentures in cash; (ii) participated in the Offering and the exercise of the Over-Allotment Option; and (iii) disposed of an aggregate of 78,000 Common Shares, resulting in a net increase in the amount of Common Shares over which it exercises control or direction of approximately of 0.73% calculated on a partially diluted basis, based on the 24,179,590 outstanding Common Shares (the “**Outstanding Shares**”) reported by the Issuer in its short form prospectus dated October 3, 2023.

3.2 State the designation and number or principal amount of securities and the eligible institutional investor’s securityholding percentage in the class of securities at the end of the month for which the report is made.

As of October 31, 2023, Armistice, on behalf of certain investment funds managed by it, exercised control or direction over:

- (i) 2,372,000 Common Shares; and
- (ii) 1,654,242 Warrants,

representing approximately 15.59% of the Outstanding Shares, calculated on a partially diluted basis.

- 3.3 If the transaction involved a securities lending arrangement, state that fact.

Not applicable

- 3.4 State the designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities to which this report relates and over which

- (a) the eligible institutional investor, either alone or together with any joint actors, has ownership and control,

Not applicable.

- (b) the eligible institutional investor, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the eligible institutional investor or any joint actor, and

Not applicable.

- (c) the eligible institutional investor, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.

Armistice exercises control or direction, but not ownership, over all of the securities referred to in items 2.2 and 3.2 above on behalf of certain investment funds managed by it over which it has discretionary trading authority. Armistice specifically disclaims any beneficial ownership of the securities referred to herein.

- 3.5 If the eligible institutional investor or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the eligible institutional investor's securityholdings.

Not applicable.

- 3.6 If the eligible institutional investor or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement. State if the securities lending arrangement is subject to the exception provided in section 5.7 of NI 62-104.

Not applicable.

- 3.7 If the eligible institutional investor or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the eligible institutional investor's economic exposure to the security of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.

Not applicable.

Item 4 – Purpose of the Transaction

State the purpose or purposes of the eligible institutional investor and any joint actors for the acquisition or disposition of securities of the reporting issuer. Describe any plans or future intentions which the eligible institutional investor and any joint actors may have which relate to or would result in any of the following:

- (a) the acquisition of additional securities of the reporting issuer, or the disposition of securities of the issuer;

The securities of the Issuer were acquired for investment purposes. Depending on market conditions and other factors, Armistice, on behalf of the investment funds managed by it, may in the future increase or decrease its ownership, control or direction over securities of the Issuer through open market transactions, private agreements or otherwise.

- (b) a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries;

Not applicable.

- (c) a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board;

Not applicable.

- (d) a material change in the present capitalization or dividend policy of the reporting issuer;

Not applicable.

- (e) a material change in the reporting issuer's business or corporate structure;

Not applicable.

- (f) a change in the reporting issuer's charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person;

Not applicable.

- (g) a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace;

Not applicable.

- (h) the issuer ceasing to be a reporting issuer in any jurisdiction of Canada;

Not applicable.

- (i) a solicitation of proxies from securityholders;

Not applicable.

- (j) an action similar to any of those enumerated above.

Not applicable.

Item 5 – Agreements, Arrangements, Commitments or Understandings With Respect to Securities of the Reporting Issuer

Describe the material terms of any agreements, arrangements, commitments or understandings between the eligible institutional investor and a joint actor and among those persons and any person with respect to securities of the class of securities to which this report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

Not applicable.

Item 6 – Change in Material Fact

If applicable, describe any change in a material fact set out in a previous report filed by the eligible institutional investor under the early warning requirements or Part 4 in respect of the reporting issuer's securities.

Not applicable.

Item 7 – Certification

The undersigned, as the eligible institutional investor, certifies, or the undersigned, as the agent filing the report on behalf of the eligible institutional investor, certifies to the best of its knowledge, information and belief, that the statements made in this report are true and complete in every respect.

DATED this 8th day of November, 2023.

ARMISTICE CAPITAL LLC

By: “Samuel Bezek”
Name: Samuel Bezek
Title: Chief Compliance Officer